FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase

被引：116

作者：

Guan, Jikui ^{[1
]}

Umapathy, Ganesh ^{[1
]}

Yamazaki, Yasuo ^{[1
]}

Wolfstetter, Georg ^{[1
]}

Mendoza, Patricia ^{[1
]}

Pfeifer, Kathrin ^{[1
]}

Mohammed, Ateequrrahman ^{[1
]}

Hugosson, Fredrik ^{[1
]}

Zhang, Hongbing ^{[2
]}

Hsu, Amy W. ^{[2
]}

Halenbeck, Robert ^{[2
]}

Hallberg, Bengt ^{[1
]}

Palmer, Ruth H. ^{[1
]}

机构：

[1] Univ Gothenburg, Sahlgrenska Acad, Dept Med Biochem & Cell Biol, Inst Biomed, Gothenburg, Sweden

[2] Five Prime Therapeut Inc, San Francisco, CA USA

来源：

ELIFE | 2015年 / 4卷

关键词：

RECEPTOR TYROSINE KINASE; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; ALK KINASE; NEUROBLASTOMA; MUTATIONS; PLEIOTROPHIN; GENE; EXPRESSION; PROTEIN;

D O I：

10.7554/eLife.09811

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a range of human cancers, including non-small cell lung cancer and neuroblastoma (Hallberg and Palmer, 2013). Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the extracellular domain of ALK and in addition to activation of wild-type ALK are able to drive 'superactivation' of activated ALK mutants from neuroblastoma. In conclusion, our data show that ALK is robustly activated by the FAM150A/B ligands and provide an opportunity to develop ALK-targeted therapies in situations where ALK is overexpressed/activated or mutated in the context of the full length receptor.

引用

页数：16

共 34 条

[31] Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism [J].

Witek, Barbara ;

El Wakil, Abeer ;

Nord, Christoffer ;

Ahlgren, Ulf ;

Eriksson, Maria ;

Vernersson-Lindahl, Emma ;

Helland, Aslaug ;

Alexeyev, Oleg A. ;

Hallberg, Bengt ;

Palmer, Ruth H. .

PLOS ONE, 2015, 10 (05)

[32] The ligand jelly belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK [J].

Yang, Hai-Ling ;

Eriksson, Therese ;

Vernersson, Emma ;

Vigny, Marc ;

Hallberg, Bengt ;

Palmer, Ruth H. .

JOURNAL OF EXPERIMENTAL ZOOLOGY PART B-MOLECULAR AND DEVELOPMENTAL EVOLUTION, 2007, 308B (03) :269-282

[33] Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome [J].

Zhang, Hongbing ;

Pao, Lily I. ;

Zhou, Aileen ;

Brace, Arthur D. ;

Halenbeck, Robert ;

Hsu, Amy W. ;

Bray, Thomas L. ;

Hestir, Kevin ;

Bosch, Elizabeth ;

Lee, Ernestine ;

Wang, Gang ;

Liu, Haixia ;

Wong, Brian R. ;

Kavanaugh, W. Michael ;

Williams, Lewis T. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (44) :15741-15745

[34] An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms [J].

Zou, Helen Y. ;

Li, Qiuhua ;

Lee, Joseph H. ;

Arango, Maria E. ;

McDonnell, Scott R. ;

Yamazaki, Shinji ;

Koudriakova, Tatiana B. ;

Alton, Gordon ;

Cui, Jingrong J. ;

Kung, Pei-Pei ;

Nambu, Mitchell D. ;

Los, Gerrit ;

Bender, Steven L. ;

Mroczkowski, Barbara ;

Christensen, James G. .

CANCER RESEARCH, 2007, 67 (09) :4408-4417

← 1 2 3 4 →